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Deep penetrating nevi (DPN) are rare melanocytic nevi, which can exhibit atypical
histological features hampering the differentiation from malignant melanoma. DPN are
considered benign melanocytic lesions, but rare spread to lymph nodes and unfavorable
clinical outcomes associated with borderline/atypical DPN (B-DPN) has been reported.
Since no guidelines are available for DPN and B-DPN, we aimed to review the literature
on DPN and B-DPN to assess the management and prognosis. We screened 3,513
references from EMBASE, Scopus and Medline databases, and included 15 studies with
a total of 355 DPN patients and 48 B-DPN patients. Therapeutic interventions ranged
from simple excision to wide excisions and sentinel lymph node biopsy (SLNB), with
block lymph node dissection in some positive SLNB cases. Follow-up periods ranged
from 3 months to 23 years during which a total of five recurrences, two in DPN and
three in B-DPN group, and three metastases, in B-DPN group, were reported. While
some of the included studies comprised clinical and histopathological correlation, few
included genetic assessment. The present review highlights the need for prospective
cohort studies applying composite measures to identify effective regimens of diagnostic
workup and treatment in DPN and B-DPN.
Keywords: deep penetrating nevus, DPN, borderline/atypical deep penetrating nevus, DPN treatment,
borderline/atypical deep penetrating nevus treatment
INTRODUCTION
The term deep penetrating nevus (DPN) was first coined by Seab et al., in 1989, the author
describing a series of cases which were initially misdiagnosed as malignant melanoma (1). Due
to its clinical and, in particular, its histopathological appearance, DPN can be challenging to
differentiate from cellular blue nevi, Spitz nevi, and malignant melanoma (2). Clinically presenting
as solitary, pigmented papules, or nodules, DPN is more common in young individuals with a
prevalent appearance in the head and neck area (3, 4). Histologically it is characterized as a well-
demarcated, wedge-shaped lesions reaching down into the reticular dermis/subcutis exhibiting
epithelioid/spindle-cell melanocytic nests with low-grade cytologic atypia and possible mitotic
figures (1, 2, 5, 6). Despite the conspicuous histopathologic appearance, DPNs have a good
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prognosis demonstrating a benign behavior (1, 2, 5, 6). However,
spread to regional lymph nodes has been described (7) and
even cases of metastasis from DPN with atypical features
classified as “borderline” (B-DPN) can be found in the literature
(7–10). Representing a diagnostic challenge, even to experts
of the dermatopathology and pathology field (7), the correct
diagnosis is paramount to effective clinical management and
outcome. Recommendations for therapeutic management and
follow-up are not consistent and not based on sufficient clinical
data. Under-treatment and over-treatment including prolonged
follow-up, is common in patients with these tumors (2, 6, 8, 9, 11,
12). We aimed to provide a review of the literature on DPN and
B-DPN assessing clinical management including treatment and
follow-up evaluation.
MATERIALS AND METHODS
We conducted a review of the Medline, Scopus, and Embase
datasets for clinical studies published from 1989 to July 30, 2019,
on DPN and B-DPN.
The words “deep penetrating nevus” and “deep nevus” were
used to identify studies examining patients with this condition
containing clinical and laboratory workup data they underwent.
Combinations of MeSH (Medical Subject Heading) terms and
boolean operators applied in our search on Medline included
are listed in the following: deep penetrating nevus OR deep
penetrating nevus OR deep blue nevus OR deep blue nevus
OR deep nevus OR deep nevus. Scopus was searched using the
following combinations of MeSH terms and boolean operators:
[(nevus) OR (Nevi) OR (Nevus) OR (Nevi)] AND [(deep) OR
(blue) OR (penetrating)]. Combinations of MeSH terms and
boolean operators used in our search on Embase included the
following: [nevus/nevus AND ((blue) OR (deep)]. We only
considered articles published in the English or German language
for further review and excluded duplicates. In order to address
the anticipated overall lack of well-designed studies in large
populations of patients with DPN and B-DPN we included
prospective studies of any design, retrospective cohort analyses
as well as case reports. However, in order to be able to
evaluate sustained effects of clinical management and prognostic
outcomes we only included those studies that contained follow-
up data. Articles were screened based on title and abstract to
determine eligibility for our review. Entire articles were reviewed
and retrieved to assess acceptability. Furthermore, we manually
searched the bibliographies of included articles.
RESULTS
The initial search identified a total of 3,513 studies and during
the review process a further three articles were identified by
manual searching of the reference lists. After duplicate articles
were eliminated, a total of 3,369 articles remained. Papers were
narrowed by title, abstract, and full-text review. A total of 15
articles, met the inclusion criteria (Figure 1). All 15 papers that
met the inclusion criteria are listed in Tables 1A,B. The studies
were categorized into articles reporting on clinical management
of DPN and those reporting on B-DPN. The included studies
consist of 10 cohort studies and five case reports including a
total of 355 patients with DPN and 48 patients with B-DPN. The
clinical characteristics and follow-up data of the studies included
are shown in Tables 1A,B.
Clinical Characteristics
For the deep penetrating nevus group the age range in studies,
excluding case report, varied from 3 months to 64 years with a
mean age of 30 years, similar to the B-DPN group where the age
range was 4–62 years with the mean age in all studies being under
30 years. The gender distribution was similar for both groups
with a slightly higher number of females, 203 (57.1%) in DPN
and 25 (54.1%) in B-DPN, than males, 152 (42.8%) in DPN, and
22 (45.8%) in B-DPN. The location of the nevus was divided
into six categories: head and neck, trunk, upper extremity, lower
extremity (including buttocks), other, and unknown. Most nevi
in the DPN group were located in the head and neck area, 117
(32.9%), and on the upper and lower extremity, 111 (31.2%). Out
of the 111 nevi on the extremities, more nevi were diagnosed on
the upper extremity than on the lower one, 61 vs. 44, respectively.
Among unusual nevi locations was the conjunctiva, with 34 DPN
cases (19), and the buccal mucosa and soft palate in one case (17).
In the B-DPN group themost frequent location was similar to the
DPN group, head and neck with 16 cases followed by the trunk
and upper extremity, each with 14 cases, and in the remaining
four cases the location being the lower extremity.
Management
Information regarding treatment management for the DPN
group was not available for all the included studies. Simple
excision without any further surgical procedures was the
main treatment the majority of the patients received. Several
cases underwent re-excision, in cases were the nevus was not
completely removed the first time, and some patients underwent
wide-excision, without further specifications in this regard. For
the B-DPN group, the treatment varied from excisions/wide
excisions to sentinel lymph node biopsies (SLNB) and systemic
treatment. The 2010 study by Magro et al., included 32 patients
with borderline melanocytic tumors out of which seven patients
had the diagnosis of a B-DPN (9). Four of those patients
had positive sentinel lymph node biopsies (SLNB). One of
those patients was initially diagnosed as DPN and the lesion
recurred after 1.5 years showing histologic characteristics of a
deeply invasive melanoma. A re-evaluation of the initial biopsy
diagnosed the lesion as a B-DPN, which in the eyes of the
authors would have had the indication for wide excision and
SLNB. The patient developed subsequent multi-organ metastasis
and died. The other patients with positive SLB underwent
completion lymphadenectomy with no further evidence of
disease and received adjuvant therapy with interferon. Patients
did not show any further recurrences or metastasis within
a 4-year follow-up. The second study by Magro et al. (8)
included 40 patients with a DPN-like borderline tumor. In
35 cases a re-excision was performed and in 23 of these
cases the procedure was a wide re-excision, residual borderline
tumor being present in 11 samples. From the 23 patients with
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FIGURE 1 | Study selection flowchart.
wide re-excision 19 underwent SLNB out of which 7 were
positive. The authors reported that in most of these positive
SLNB cases, the tumor deposits were subcapsular and small,
while in one patient, who presented a 1-year recurrence post-
treatment there were extensive parenchymal deposits. Complete
lymphadenectomy was performed in four of the patients with
positive SLNB with no further evidence of disease and two
patients received adjuvant therapy with interferon alpha. In
two of the 40 cases, the initial diagnosis was of a dysplastic
nevus and a cellular blue nevus, the patients receiving small
conservative re-excision or no re-excision, respectively. Both
patients developed plexiform melanomas in the vicinity of the
previous lesion with metastatic disease due to which both
patients died. One case report was included in this group, a
4-year-old boy with a lesion on his neck diagnosed as DPN
who developed a visible and palpable lymph node 4 months
after treatment. SLNB revealed pigmented atypical cells and the
boy underwent comprehensive type II modified radical neck
dissection with the removal of 39 lymph nodes, all negative.
Staging revealed no further evidence of metastasis. Re-evaluation
of the primary biopsy led to re-diagnosis of the lesion as a
malignant melanoma.
Follow-Up
The follow-up of the patients in the DPN group ranged from 4
months to 23 years. In five studies, some patients had a follow-
up that lasted longer than 10 years. Out of the 12 studies, local
recurrences were reported just in two patients from two different
studies and no cases of metastasis were observed. Follow-up in
the B-DPN group ranged from 5 months to 5 years. A total of
four recurrences and three deaths were observed, all three cases
being misdiagnosed initially which lead to an undertreatment of
the patients.
DISCUSSION
The histologic diagnosis of atypical melanocytic tumors can
be very challenging even for experienced dermatopathologists
and pathologistis (7) and differentiating between a benign or
malignant lesions has therapeutic and prognostic consequences.
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TABLE 1A | Clinical data of patients included in the DPN group.
ID No. of
cases
Gender (No.) Age, range
(mean), years
Location (No.) Follow-up,
range
Local
recurrence
(No.)
Metastasis
(No.)
Source
Male Female Head and
neck
Trunk Upper
extremity
Lower
extremity
Other Unknown
1 70 33 37 3–63 (NA) 29 8 15 12 6 0 1–23 y 0 0 (1)
2 10 5 5 u−49 (22) 2 4 4 0 0 0 4–13 y 0 0 (11)
3 41 15 26 4–47 (25) 13 11 11 6 0 0 4–76m 0 0 (6)
4 14 7 7 17–36 (26) 6 1 6 0 1 1/2–8 y 0 0 (13)
5 31 14 17 3–56 (26) 12 7 2 7 0 3 1–17 y 1 0 (2)
6 146 61 85 4–64 (28) 52 51 28 15 0 0 1/2–13 y 1 0 (12)
7 1 1 0 3m 0 0 0 1 0 0 15m 0 0 (14)
8 1 1 0 59 0 0 1 0 0 0 202m 0 0 (15)
9 1 0 1 56 0 0 0 1 0 0 4 y 0 0 (16)
10 1 0 1 49 0 0 0 0 1 (buccal
mucosa and
soft palate)
0 1 y 0 0 (17)
11 5 0 5 26–56 (41) 3 0 0 2 0 0 30m 0 0 (18)
12 34 15 19 7–51 (25) 0 0 0 0 34
(conjunctiva)
0 0.3–16.3 y 0 0 (19)
Total 355
(100%)
152
(42.8%)
203
(57.1%)
3 m−64 y 117
(32.9%)
82
(23%)
111
(31.2%)
111
(31.2%)
41 (11.5%) 4 (1.1%) 4 m−23 y 2 0
Twelve studies were included in the DPN group. Information on clinical characteristics as well as follow-up data was extracted from each study and is presented in the table. NA,
indicates not available; m, months; y, years.
Despite the fact that DPN has been vastly described as a
benign melanocytic lesion (1, 6, 11, 13, 18, 19) its malignant
potential has being discussed intensely (5, 7) and cases with
regional lymph node involvement have been reported (2, 5,
12). However, the 2009 International Melanoma Pathology
Study Group agreed that distant disease beyond the regional
nodes is rare and that in the absence of mitotic activity,
nuclear pleomorphism, and expansive growth, <2% of the
lesions spread to the lymph node (5). During the 2008 “XXIX
Symposium of the International Society of Dermatopathology
in Graz” expert dermatopathologistis and pathologists reviewed
57 cases of MELTUMP (Melanocytic Tumors of Uncertain
Malignant Potential) which included atypical Spitz tumors
(AST) and atypical epithelioid/spindled blue nevi, the latter
category including DPNs (7). The patients were stratified in
three groups with a favorable (no metastatic disease during
a 5 year follow-up), unfavorable (tumor-related death and/or
lymph node and/or visceral metastasis), and borderline (nodal
tumor cell deposits ≤ 0.2mm) behavior and the authors noted
that the unfavorable group presented more frequently three
histopathologic features, namely presence of mitosis, mitosis
near the base, and inflammatory reaction. Furthermore, the
authors commented on the difficulty of reaching a consensus
regarding the benign or malignant diagnosis of the lesions.
Cases of metastatic DPN have been reported also by other
groups, mentioning that these lesions presented “borderline” or
“atypical” features (8–10), hinting at the uncertain malignant
potential of these lesions where the diagnosis and therapeutic
management is challenging. In the present review, we divided
the included studies into two groups, DPN and B-DPN. A
total of 355 patients were included in the DPN group and
during a follow-up period ranging from 4 months to 23 years
only two local recurrences were reported and no metastasis. In
the second group, B-DPN, 48 patients were included with 24
patients undergoing SLNB and five block lymph node dissection
after positive SLNB, and some patients even receiving adjuvant
interferon alpha therapy afterwards. In this “high risk” group
the recurrence rate was low, four patients developing local
recurrences, and three widespread metastatic diseases. The fact
that none of the patients in the DPN group developed metastatic
disease and that even though 12 patients from the B-DPN group
had positive SLNB only three, two being initially misdiagnosed,
developed widespread metastatic disease, highlights the benign
behavior of this melanocytic lesion. However, based on the two
studies by Magro et al. (8, 9) it should be further evaluated and
investigated if a broader initial surgical approachwould not prove
to be beneficial for patients with borderline/atypical DPN.
Even though the age at diagnosis for DPN and for B-DPN
displayed a wide range from 3 months to 64 years, in our
review the lesions were usually diagnosed in young individuals
before the age of 30 years (1, 6, 8, 9). Congenital DPN have
been previously reported in the literature (6) but most DPN
are acquired lesions (3). In one case included in our review,
the authors report on a DPN developing in a congenital nevus
of the right popliteal fossa of a 3-month old boy (14). The
initial excision of the lesion showed positive deep margins due
to which the patient underwent a re-excision having afterwards
no further evidence of recurrence or metastasis during a 15
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TABLE 1B | Clinical data of patients included in the B-DPN group.
ID No. of
cases
Gender (No.) Age, range
(mean), years
Location (No.) Lymph node involvement and further treatment Follow-up,
range
Local
recurrence
(No.)
Metastasis
(No.)
Source
Male Female Head and
neck
Trunk Upper
extremity
Lower
extremity
Other Unknown
1 7 5 2 14–36 (22.3) 1 2 4 0 0 0 Four patients had positive sentinel lymph nodes
(SLN). Patients underwent completion
lymphadenectomy with no further evidence of
disease and received adjuvant therapy with
interferon
4 y 1 1 (9)
2 40 16 24 10–62 (34.5) 14 12 10 4 0 0 Nineteen patients underwent sentinel lymph node
biopsy with positive SLN in seven cases. 4/7
underwent completion lymphadenectomy with no
further evidence of disease. Two patients received
adjuvant interferon alpha therapy
5 m−5.42 y 3 2 (8)
3 1 1 0 4 1 0 0 0 0 0 Initially, no lymphadenopathy. After 4
months—excision of a visible and palpable lymph
node with pigmented atypical cells followed by a
type III modified radical neck dissection with
removal of 39 lymph nodes which were negative
8m 0 0 (20)
Total 48
(100%)
22
(45.8%)
26
(54.1%)
4–62 y 16 (33.3%) 14
(29.1%)
14
(29.1%)
4 (8.3%) 0 0 – 5 m−5.42 y 4 3
Three studies were included in the B-DPN group. Information on clinical characteristics and treatment management, as well as follow-up data was extracted from each study and is presented in the table. M, months; y, years.
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months follow-up period. The youngest B-DPN case found
was the 4-year-old boy initially diagnosed with a DPN but re-
diagnosed as a melanoma after a lymph node metastasis was
identified 4 months later. The boy did not show any further
metastatic disease, however he did undergo a type III modified
radical neck dissection with the excision of 39 lymph nodes, all
histological negative. The differential diagnosis between a DPN
and malignant melanoma in children can be difficult as DPN can
demonstrate cytological atypia and presence of mitotic activity,
raising suspicion of malignancy (2). The authors mentioned
that they considered the diagnosis of a pigmented epithelioid
melanocytoma but because not all histologic criteria were met the
diagnosis was changed to melanoma (20). It would be interesting
to re-evaluate the lesion and determine if applying the criteria
mentioned in more recent studies (7–9) the lesion would be
better classified as a borderline/atypical DPN.
A recent publication looking at the genetics of melanocytic
lesions with histological aspects of DPN has made observations
distinguishing this entity from other melanocytic tumors (21).
Aside from harboring mutations activating the MAP kinase
pathway (i.e., MAP2K1 or BRAF), also observed in other
nevi, it became apparent DPN have frequent concurrent
CTNNB1 mutations. This leads to continuous activation of
the beta-catenin signaling pathway. This was also observable
histologically. In conventional nevi, melanocytes become smaller
(“mature”) and show lower expression of CTNNB1 and
CCND1 by immunohistochemistry in the deeper dermis. In
DPN, the cells do no become smaller (“mature”) and retain
expression of CTNNB1 and CCND1 in the lower dermis.
The authors also identified that malignant DPN (melanomas
arising in DPN) demonstrated additional genetic alterations
(to MAP kinase activating and CTNNB1 mutations). These
findings have a number of relevant implications. CTNNB1
immunohistochemistry can be useful to identify DPN lesions (19,
22). Additionally, the mutation profile can aid in differentiating
blue nevi (which have GNAQ or GNA11 mutations (23)) from
DPN, which can be difficult based solely on histological criteria.
Lastly, the presence of additional genetic events such as TERT
promoter, CDKN2A, TP53, or other mutations, argues for a
malignant tumor and poor prognosis.
The recently described genetic findings could be of
considerable aid in correctly diagnosed DPN and B-DPN.
These genetic findings were included in the latest WHO
classification system for melanocytic tumors, which placed
DPN and B-DPN between common nevi and melanomas in
the intermediate/melanocytoma groups, with DPN labeled low-
grade and B-DPN a high-grade dysplasia (24). Detailed follow-up
studies which apply the genetic criteria presented by Yeh et al.
are currently lacking. Of particular value would of course be
a larger prospective study. This data could potentially further
refine the model proposed by Yeh et al. and allow a genetically
based more precise estimation of a tumors behavior in cases
where these are difficult to classify based on histopathological
assessment alone.
The strength of our review is highlighting a substantial
lack of prospective cohort studies combining clinical and
histopathological correlation with genetic assessment to identify
effective strategies for the clinical management of DPN and B-
DPN. At the same time, the low number of included studies
is a limitation for an appropriate statistical analysis in the
management on DPN and borderline/atypical DPN.
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